drugset / Trial / NCT00653042

Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA

NCT00653042

Phase 2 Completed 305 enrolled Scios, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the effects of nesiritide compared to placebo when given with standard of care therapies, on kidney function, heart function and the need of other treatments in heart failure patients undergoing heart bypass graft surgery that requires the use of a cardiopulmonary bypass machine (CPB pump or heart-lung machine).

Timeline

Start
2004-03
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.01 ug/kg Intravenous